AI Engines For more Details: Perplexity Kagi Labs You
Research Tool: Proadifen hydrochloride is primarily used as a research tool in pharmacology and toxicology to study the metabolism and pharmacokinetics of drugs and other xenobiotics. By inhibiting specific cytochrome P450 enzymes, proadifen hydrochloride can help researchers investigate the role of these enzymes in drug metabolism, drug interactions, and toxicity.
Drug Metabolism: Cytochrome P450 enzymes play a crucial role in the metabolism of a wide range of drugs, including medications used to treat various medical conditions. By inhibiting cytochrome P450 activity, proadifen hydrochloride can alter the pharmacokinetics and bioavailability of co-administered drugs, potentially leading to changes in their efficacy and safety profiles.
Drug Interactions: Proadifen hydrochloride has been studied for its potential to modulate drug metabolism and drug interactions. By inhibiting cytochrome P450 enzymes involved in the metabolism of multiple drugs, proadifen hydrochloride can affect the clearance and plasma concentrations of co-administered medications, leading to potential interactions and adverse effects.
Toxicity Studies: Proadifen hydrochloride has been used in preclinical toxicology studies to investigate the metabolic pathways and potential toxic effects of xenobiotics. By inhibiting cytochrome P450 enzymes, proadifen hydrochloride can alter the metabolism of test compounds and facilitate the identification of metabolites that may contribute to toxicity.
Experimental Applications: Proadifen hydrochloride has been investigated for its potential therapeutic applications in conditions such as cancer and neurodegenerative diseases. Some studies have suggested that cytochrome P450 inhibitors like proadifen hydrochloride may enhance the efficacy of certain chemotherapeutic agents by inhibiting drug metabolism and increasing drug exposure in tumor tissues. However, further research is needed to evaluate the safety and effectiveness of proadifen hydrochloride for therapeutic purposes.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 4.9 | 0.6 | 7.17 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.3 | 3.4 | -0.03 |
| Allergies | 7.1 | 3.9 | 0.82 |
| Allergy to milk products | 2.6 | 1.6 | 0.63 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 6.4 | 7.6 | -0.19 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 4.2 | 1.6 | 1.63 |
| Ankylosing spondylitis | 5.3 | 1.3 | 3.08 |
| Anorexia Nervosa | 1.6 | 3.2 | -1 |
| Antiphospholipid syndrome (APS) | 2.1 | 0.3 | 6 |
| Asthma | 5.8 | 3.3 | 0.76 |
| Atherosclerosis | 2.4 | 2.4 | 0 |
| Atrial fibrillation | 4.1 | 3.1 | 0.32 |
| Autism | 11.2 | 11.6 | -0.04 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 2.3 | 2.3 | |
| Bipolar Disorder | 2.4 | 1.7 | 0.41 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 0.7 | 0.7 | |
| Cancer (General) | 0.6 | 2.9 | -3.83 |
| Carcinoma | 4.1 | 2.6 | 0.58 |
| Celiac Disease | 3.6 | 4.1 | -0.14 |
| Cerebral Palsy | 1.7 | 1.3 | 0.31 |
| Chronic Fatigue Syndrome | 6.2 | 7.7 | -0.24 |
| Chronic Kidney Disease | 5 | 3.3 | 0.52 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 2.4 | 1.7 | 0.41 |
| Chronic Urticaria (Hives) | 2 | 1.8 | 0.11 |
| Coagulation / Micro clot triggering bacteria | 2 | 1.3 | 0.54 |
| Cognitive Function | 2.5 | 1.6 | 0.56 |
| Colorectal Cancer | 7.6 | 2.8 | 1.71 |
| Constipation | 2.1 | 0.7 | 2 |
| Coronary artery disease | 2.9 | 3 | -0.03 |
| COVID-19 | 11.2 | 13.8 | -0.23 |
| Crohn's Disease | 9.3 | 6.5 | 0.43 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1.2 | 1.9 | -0.58 |
| d-lactic acidosis (one form of brain fog) | 0.7 | 0.7 | |
| deep vein thrombosis | 2.5 | 1.4 | 0.79 |
| Denture Wearers Oral Shifts | 1 | 1 | |
| Depression | 13.1 | 10.4 | 0.26 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.8 | 2.3 | -0.28 |
| Endometriosis | 3.5 | 2.7 | 0.3 |
| Eosinophilic Esophagitis | 0.6 | -0.6 | |
| Epilepsy | 4 | 2.7 | 0.48 |
| erectile dysfunction | 1.1 | 0.3 | 2.67 |
| Fibromyalgia | 3.1 | 2.6 | 0.19 |
| Functional constipation / chronic idiopathic constipation | 6.9 | 4.9 | 0.41 |
| gallstone disease (gsd) | 4.3 | 1.2 | 2.58 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.5 | 1.2 | 0.25 |
| Generalized anxiety disorder | 3.4 | 2.3 | 0.48 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.4 | 0.8 | 2 |
| Graves' disease | 1.9 | 3.3 | -0.74 |
| Gulf War Syndrome | 0.9 | 2.4 | -1.67 |
| Halitosis | 0.9 | 0.3 | 2 |
| Hashimoto's thyroiditis | 4 | 2.1 | 0.9 |
| Heart Failure | 4.7 | 2.2 | 1.14 |
| hemorrhagic stroke | 1 | 1 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 1.9 | 0.6 | 2.17 |
| hypercholesterolemia (High Cholesterol) | 1.1 | 0.6 | 0.83 |
| hyperglycemia | 2.6 | 2.1 | 0.24 |
| Hyperlipidemia (High Blood Fats) | 1.2 | 0.3 | 3 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 5.6 | 6.1 | -0.09 |
| Hypothyroidism | 0.4 | 1 | -1.5 |
| Hypoxia | 3.9 | 0.3 | 12 |
| IgA nephropathy (IgAN) | 1.6 | 5.3 | -2.31 |
| Inflammatory Bowel Disease | 8.1 | 11.7 | -0.44 |
| Insomnia | 2.1 | 3.4 | -0.62 |
| Intelligence | 2 | 0.6 | 2.33 |
| Intracranial aneurysms | 1.2 | 0.6 | 1 |
| Irritable Bowel Syndrome | 9.1 | 6.3 | 0.44 |
| ischemic stroke | 3.3 | 1.7 | 0.94 |
| Liver Cirrhosis | 7.7 | 5.6 | 0.38 |
| Long COVID | 7.6 | 8.9 | -0.17 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1.5 | 1.6 | -0.07 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.9 | 0.9 | 0 |
| ME/CFS with IBS | 1.1 | 2.4 | -1.18 |
| ME/CFS without IBS | 1.8 | 2.4 | -0.33 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 2.1 | 0.9 | 1.33 |
| Metabolic Syndrome | 8.9 | 8.6 | 0.03 |
| Mood Disorders | 12.9 | 8.9 | 0.45 |
| multiple chemical sensitivity [MCS] | 1.2 | 0.1 | 11 |
| Multiple Sclerosis | 8 | 6.9 | 0.16 |
| Multiple system atrophy (MSA) | 1.6 | 0.7 | 1.29 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 3 | -9 |
| Neuropathy (all types) | 1.1 | 2.2 | -1 |
| neuropsychiatric disorders (PANDAS, PANS) | 1.2 | 1.2 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5.7 | 5.8 | -0.02 |
| NonCeliac Gluten Sensitivity | 1.9 | 0.6 | 2.17 |
| Obesity | 11.8 | 8.7 | 0.36 |
| obsessive-compulsive disorder | 7 | 4.7 | 0.49 |
| Osteoarthritis | 2.6 | 1.5 | 0.73 |
| Osteoporosis | 2.5 | 1.9 | 0.32 |
| pancreatic cancer | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 10.1 | 7.2 | 0.4 |
| Polycystic ovary syndrome | 7.4 | 3.6 | 1.06 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.4 | -0.17 |
| Primary sclerosing cholangitis | 2.6 | 3 | -0.15 |
| Psoriasis | 4.3 | 4 | 0.07 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 8.8 | 4.4 | 1 |
| Rosacea | 1.2 | 0.7 | 0.71 |
| Schizophrenia | 7.4 | 3.4 | 1.18 |
| scoliosis | 0.9 | 1.2 | -0.33 |
| Sjögren syndrome | 3.2 | 3.2 | 0 |
| Sleep Apnea | 1.9 | 1.8 | 0.06 |
| Slow gastric motility / Gastroparesis | 1.5 | 0.3 | 4 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 2 | 0.6 | 2.33 |
| Stress / posttraumatic stress disorder | 3.3 | 3.3 | 0 |
| Systemic Lupus Erythematosus | 4.4 | 2.2 | 1 |
| Tic Disorder | 1.5 | 1.8 | -0.2 |
| Tourette syndrome | 1.2 | 0.3 | 3 |
| Type 1 Diabetes | 5.1 | 4.4 | 0.16 |
| Type 2 Diabetes | 9.9 | 8.7 | 0.14 |
| Ulcerative colitis | 5.8 | 8.1 | -0.4 |
| Unhealthy Ageing | 5.8 | 2.8 | 1.07 |
| Vitiligo | 2.5 | 1.9 | 0.32 |
